---
schema_version: "secwatch.filing_event.v1"
accession: "0001213900-23-050967"
form_type: "8-K"
ticker: "MDAI"
cik: "0001833498"
company_name: "Spectral AI, Inc."
filed_at: "2023-06-22T23:59:59+00:00"
generated_at: "2026-06-13T19:17:50.285850+00:00"
event_type: "m_and_a"
sentiment: "neutral"
materiality_score: 0.55
calibrated_materiality_score: 0.55
confidence: "high"
source: SEC EDGAR
---

# Rosecliff Acquisition Corp I furnishes investor presentation for proposed Spectral MD business combination

## Summary
- DeepView System received FDA Breakthrough Device Designation for burn indication in 2018.
- Spectral MD has secured over $130 million in U.S. government contracts for burn and DFU development.
- Initial target markets (burn wounds + diabetic foot ulcers) estimated at ~$14.7 billion by 2028.
- Proprietary AI database contains more than 263 billion clinically validated data points.
- Regulatory submissions (FDA, CE, UKCA) expected to commence in 2023 based on positive study outcomes.

## SEC filing metadata
- accession: 0001213900-23-050967
- form_type: 8-K
- ticker: MDAI
- cik: 0001833498
- company_name: Spectral AI, Inc.
- filed_at: 2023-06-22T23:59:59+00:00
- event_type: m_and_a
- sentiment: neutral
- materiality_score: 0.55
- calibrated_materiality_score: 0.55
- confidence: high
- sec_items: 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1833498/000121390023050967/0001213900-23-050967-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1833498/000121390023050967/ea180775-8k425_rosecliff.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001213900-23-050967
- JSON: https://secwatch.observer/filing/0001213900-23-050967.json
- Plain text: https://secwatch.observer/filing/0001213900-23-050967.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.